Patient specific data were extracted from electronic medical records including demographic data, laboratory results (including creatinine, hemoglobin (Hb), C-reactive protein (CRP), leucocyte count, hs-cTnT and NT-proBNP) and angiographic measurements using the cardiac Research Data Warehouse (RWH). LVEF was assessed during cardiac catherization. The highest laboratory values that were assessed between 7 days prior to 7 days after the cardiac catherization were considered for further analysis. The oncological diagnosis (ICD-10 code), date of diagnosis and treatment were retrieved from the Clinical Registry of the National Centre for Tumor Diseases (NCT) Heidelberg. Data of all-cause mortality and date of death were obtained from the registration office from the patients’ place of residence. Follow-up of ACM was analyzed by October 1, 2020.
Measurement of hs-cTnT in plasma samples was performed using the Elecsys® Troponin T high sensitive hs-cTnT assay (Roche Diagnostics) in the central laboratory at Heidelberg University Hospital. Limit of blank (LoB), Limit of detection (LoD), 10% coefficient of variation (CV) and 99th percentile cut-off values for the hs-cTnT assay were 3, 5, 13 and 14 ng/L. NT-proBNP was measured at the same timepoint using the Stratus® CS Acute Care™ NT‐proBNP assay (Siemens AG, Berlin and Munich, Germany).
Measurement of hs-cTnT in plasma samples was performed using the Elecsys® Troponin T high sensitive hs-cTnT assay (Roche Diagnostics) in the central laboratory at Heidelberg University Hospital. Limit of blank (LoB), Limit of detection (LoD), 10% coefficient of variation (CV) and 99th percentile cut-off values for the hs-cTnT assay were 3, 5, 13 and 14 ng/L. NT-proBNP was measured at the same timepoint using the Stratus® CS Acute Care™ NT‐proBNP assay (Siemens AG, Berlin and Munich, Germany).